43.7 F
Fort Worth
Wednesday, October 28, 2020
Business Fort Worth eye medication firm acquired for $225M

Fort Worth eye medication firm acquired for $225M

Other News

Fort Worth Film Commission & Lone Star Film Festival panels and film talks

Lone Star Film Festival (LSFF) and the Fort Worth Film Commission (FWFC) announce eight virtual panels and eight...

Dow sinks 943 points as surging virus plagues Wall Street

By STAN CHOE, DAMIAN J. TROISE and ALEX VEIGA AP Business Writers The Dow Jones Industrial Average sank 943...

Breeders’ Cup Classic may feature Triple Crown race winners

By BETH HARRIS AP Racing Writer Kentucky Derby winner Authentic heads a field of 11 horses, possibly including filly...

AP Explains: The rule that made the modern internet

By BARBARA ORTUTAY AP Technology Writer OAKLAND, Calif. (AP) — Twenty-six words tucked into a 1996 law overhauling telecommunications...

Fort Worth eye medication firm acquired for $225M

Fort Worth-based Eyevance Holdings LLC, founded in 2017 to provide medication to eye doctors, has been acquired by Santen Holdings LLC for $225 million, the companies announced on Sept. 17. Under the agreement Santen, a wholly owned subsidiary of Santen Pharmaceutical Co. Ltd., acquires all of outstanding shares of Eyevance.

Eyevance develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic, anti-fungal, anti-infective/anti-inflammatory fixed combination, and tear lubricant products. Eyevance’s current commercialization strategy is supported by a national sales team exclusively targeting ophthalmologists, The optometrists, and allergists throughout the U.S.
The company was founded by Jerry St. Peter, CEO, and director, and Jason Werner,  chief operating officer.

“Eyevance is proud of its accomplishments over the past three years and looks forward to joining Santen, one of the leading ophthalmic companies worldwide, with its innovative R&D expertise and legacy of global success,” said the co-founders in a statement. “We are excited to become part of Santen’s U.S. organization, to work in collaboration to further strengthen the existing commercial business. As Eyevance embarks on this new journey with Santen, we sincerely appreciate the Eyevance Team and its shareholders for their unwavering support and continuous pursuit of excellence.”

The transaction has been closed simultaneously with the execution of the agreement, paid all in cash, thereby making Eyevance a wholly-owned subsidiary of Santen. VISOVANQ (sterile vancomycin ophthalmic ointment) and NEXAGON (ophthalmic gel for persistent corneal epithelial defects), both of which were being developed by Eyevance, were carved out of the transaction with Santen and are excluded from this purchase.

Since inception in 2017, Eyevance has developed and commercialized topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic, anti-fungal, anti-infective/anti-inflammatory fixed combination, and tear lubricant products. Eyevance’s current commercialization strategy is supported by a national sales team exclusively targeting ophthalmologists, optometrists, and allergists throughout the U.S. which will be acquired by Santen.
In 2019, Eyevance raised $30 million in an equity funding round shortly after it acquired TOBRADEX ST and NATACYN from Swiss pharmaceutical giant Novartis.
The transaction has been closed simultaneously with the execution of the agreement, with purchase price as $225 million (USD) and paid all in cash, thereby making Eyevance a wholly-owned subsidiary of Santen. VISOVANQ (sterile vancomycin ophthalmic ointment) and NEXAGON (ophthalmic gel for persistent corneal epithelial defects), both of which were being developed by Eyevance, were carved out of the transaction with Santen and are excluded from this purchase.
The financial impact of this agreement on Santen’s FY2020 and medium-term earnings forecasts is expected to be minor. 

https://www.santen.com

Eyevance logo

https://www.santen.com

Latest News

Dow sinks 943 points as surging virus plagues Wall Street

By STAN CHOE, DAMIAN J. TROISE and ALEX VEIGA AP Business Writers The Dow Jones Industrial Average sank 943...

Four Dallas bars suspended by TABC

Four bars in Dallas have been issued an emergency order for a 30-day permit suspension from the Texas Alcoholic Beverage Commission after...

Tarrant County reports 5 COVID deaths

Tarrant County Public Health on Wednesday, Oct. 28 reported five COVID-19 deaths.The deceased include two women from Fort Worth in their 70s,...

VanTrust building 75-acre logistics hub in South Fort Worth

VanTrust Real Estate LLC, a full-service commercial real estate development company, recently broke ground on a 75-acre Fort Worth Logistics Hub in...

Topgolf, Callaway merge in $2B deal

Callaway (NYSE: ELY) and Topgolf Entertainment Group of Dallas on Oct. 28 announced that the companies have entered into...